Skip to content

Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.

Iron Metabolism Disorders in Patients With Sepsis or Septic Shock. Diagnosis and Monitoring of Treatment Based on Standard and New Laboratory Parameters.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05217836
Enrollment
90
Registered
2022-02-01
Start date
2021-09-24
Completion date
2022-12-31
Last updated
2022-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia of Chronic Disease, Iron-deficiency, Iron Deficiency Anemia, Sepsis, Septic Shock

Keywords

ferritin, transferrin, transferrin saturation, hepcidin, reticulocyte hemoglobin content, parenteral iron

Brief summary

Anemia is a common health problem. Depending on a geographical region, anemia affects even 50% of population. Among patients admitted to the intensive care unit (ICU) anemia may affect as much as 66% of patients. Moreover, many patients develop anemia during the ICU stay. In general population the most common cause of anemia is iron deficiency (ID). The investigators lack information on the incidence of ID and anemia of inflammation (AI) with absolute ID (mixed type of anemia: AI + IDA) or functional ID (AI) in patients with sepsis or septic shock hospitalised in the ICU. Therefore, the aim of the study is to improve diagnosis of iron deficiency (ID) and anemia of inflammation (AI) with absolute ID (AI + IDA) or functional ID (AI) in patients with sepsis or septic shock. ID have negative effects on the body and is associated with impaired production of proteins responsible for transport of oxygen in the blood (hemoglobin) and oxygen storage (myoglobin), and impaired immune function. Development of anemia is associated with well documented complications: organ hypoxia, myocardial infarction, stroke, infection. Replenishment of iron at this early stage may potentially prevent IDA. It is advantageous to replenish iron stores in order to avoid these complications, especially in patients with sepsis or septic shock. In IDA red blood cell transfusion is not recommended as it leads to other numerous complications. Therefore the patients presenting with laboratory results suggesting ID will receive divided doses od parenteral iron. Monitoring of iron replenishment will be based on a new laboratory parameter- reticulocyte hemoglobin equivalent.

Interventions

DIAGNOSTIC_TESTferritin; iron; transferrin; transferrin saturation; hemoglobin in reticulocyte; hepcidin

All patients will have the following laboratory parameters determined: ferritin, iron, transferrin, transferrin saturation, hemoglobin in reticulocyte, hepcidin. Patients with hemoglobin in reticulocyte below reference range will receive parenteral iron.

Sponsors

Medical University of Silesia
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* diagnosis of sepsis or septic shock according to the third international definition and appropriate diagnostic criteria

Exclusion criteria

* active bleeding * erythrocyte mean corpuscular volume (MCV) above the reference range * diagnosed thalassemia or suspicion of thalassemia based on Mentzer index \[9\] * pregnancy

Design outcomes

Primary

MeasureTime frameDescription
To assess in patients with sepsis or septic shock the incidence of: iron deficiency, anemia of inflammation with absolute iron deficiency, anemia of inflammation with functional iron deficiencyThrough study completion, an average of 1 yearIncidence of the abovementioned conditions in numbers (%) in patients with sepsis or septic shock based on the results of hemoglobin, hepcidin, reticulocyte hemoglobin equivalent (RET-He)
To analyze associations between standard (ferritin; transferrin saturation) and new (hepcidin; reticulocyte hemoglobin equivalent) laboratory tests used in diagnosis of anemia in patients with sepsis or septic shockThrough study completion, an average of 1 yearPresence or lack of correlation between the abovementioned laboratory tests
To assess the utility of a new diagnostic parameter of iron deficiency (reticulocyte hemoglobin equivalent) in monitoring treatment of iron deficiency in patients with sepsis or septic shockThrough study completion, an average of 1 yearAssessment of the effect of divided doses of parenteral iron on concentration of reticulocyte hemoglobin equivalent (determinations performed in time intervals of 3-5 days) in patients with sepsis or septic shock
To assess the effect of divided doses of parenteral iron on anemia in patients with sepsis or septic shock without chronic kidney disease or acute kidney injury requiring renal replacement therapyThrough study completion, an average of 1 yearChanges in hemoglobin concentration with consideration of iatrogenic blood loss (blood withdrew for laboratory tests)
To assess the effect of divided doses of parenteral iron and erythropoiesis- stimulating agent (epoetin alpha) on anemia in patients with sepsis or septic shock with chronic kidney disease or acute kidney injury requiring renal replacement therapyThrough study completion, an average of 1 yearChanges in hemoglobin concentration with consideration of iatrogenic blood loss (blood withdrew for laboratory tests)

Countries

Poland

Contacts

Primary ContactPiotr F Czempik, MD, PhD
pczempik@sum.edu.pl0048327894201
Backup ContactAgnieszka Wiórek, MD
agnieszka.wiorek@gmail.com0048327894201

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026